Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Delamanid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,819Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Plans to Restrict Open Market Access to Tuberculosis Medicines
    Plans to Restrict Open Market Access to Tuberculosis Medicines

    27 Jun 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/plans-to-restrict-open-market-access-to-tuberculosis-medicines/articleshow/122098065.cms

    ECONOMICTIMES
    27 Jun 2025
    Share Share
    Getting patented meds on NLEM list an uphill battle says committee member
    Getting patented meds on NLEM list an uphill battle says committee member

    15 Sep 2022

    // Teena Thacker ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/getting-patented-meds-on-nlem-list-an-uphill-battle-says-committee-member/articleshow/94213010.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    Teena Thacker ECONOMIC TIMES
    15 Sep 2022
    Share Share
    Diabetes, patented TB, HIV drugs enter essential list
    Diabetes, patented TB, HIV drugs enter essential list

    13 Sep 2022

    // Teena Thacker ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/diabetes-patented-tb-hiv-drugs-enter-essential-list/articleshow/94185393.cms

    Teena Thacker ECONOMICTIMES
    13 Sep 2022
    Share Share
    Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet
    Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet

    06 Oct 2021

    // JIHO

    https://pj.jiho.jp/article/245342

    JIHO
    06 Oct 2021
    Share Share
    Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary
    Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary

    25 May 2020

    // PRESS RELEASE

    https://www.otsuka.co.jp/en/company/newsreleases/2020/20200525_1.html

    PRESS RELEASE
    25 May 2020
    Share Share
    Delamanid, Bedaquiline-based therapy to be boosted to tackle MDR TB
    Delamanid, Bedaquiline-based therapy to be boosted to tackle MDR TB

    08 Feb 2019

    // PHARMA BIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=114048&sid=1

    PHARMA BIZ
    08 Feb 2019
    Share Share